CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $17.25M, lower than 95% of all stocks globally
- Interpretations8 currently firing — 8
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.42%
Annual Rate
KRW 50.00Paid annual
Payout Ratio
6.5%Sustainable
Last Ex-Dividend
Dec 29, 2025
The reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
711.65BKRW512.78M · vs all stocks (USD)
Revenue (TTM)
23.94BKRW17.25M · vs all stocks (USD)
Profit Margin
-111.85%vs Biotechnology peers
Beta
0.6210xvs all stocks
52-Week Change
10.02%vs all stocks
Market Capitalization
711.65BKRW512.78M · vs all stocks (USD)
Enterprise Value
515.71BKRW371.60M · vs all stocks (USD)
Forward P/E
9.34xvs Biotechnology peers
Price to Sales (TTM)
29.72xvs Biotechnology peers
Price to Book (MRQ)
5.36xvs Biotechnology peers
Enterprise to Revenue
21.54xvs Biotechnology peers
Enterprise to EBITDA
-83.39xvs Biotechnology peers
Gross Margin
47.40%vs Biotechnology peers
Profit Margin
-111.85%vs Biotechnology peers
Operating Margin
-85.95%vs Biotechnology peers
Return on Assets (TTM)
-4.98%vs Biotechnology peers
Return on Equity (TTM)
-29.25%vs Biotechnology peers
Revenue (TTM)
23.94BKRW17.25M · vs all stocks (USD)
Revenue per Share (TTM)
548.73KRWUpdated Aug 20, 2026Quarterly Revenue Growth
-58.20%vs Biotechnology peers
Gross Profit (TTM)
5.45BKRW3.92M · vs all stocks (USD)
EBITDA (TTM)
42.67BKRW30.74M · vs all stocks (USD)
Net Income (TTM)
-26.78BKRW-19.30M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
35.75%vs Biotechnology peers
Operating Cash Flow (TTM)
-7.55BKRW-5.44M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-5.79BKRW-4.17M · vs all stocks (USD)
Trailing Annual Dividend Rate
50.00KRWUpdated Aug 20, 2026Trailing Annual Dividend Yield
0.42%vs all stocks
Payout Ratio
6.45%vs Biotechnology peers
Revenue
114.06BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
63.38BKRWFY2025 · Dec 31, 2025Gross Profit
50.68BKRWFY2025 · Dec 31, 2025Operating Income
34.30BKRW24.72M · vs all stocks (USD)
Pre-tax Income
34.77BKRWFY2025 · Dec 31, 2025Income Tax Expense
-5.52BKRWFY2025 · Dec 31, 2025Net Income
40.29BKRWFY2025 · Dec 31, 2025EBIT
34.91BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
37.85BKRWFY2025 · Dec 31, 2025Research & Development
6.71BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
3.36BKRWFY2025 · Dec 31, 2025Non-operating Interest Income
770.58MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
145.25MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
40.29BKRWFY2025 · Dec 31, 2025Operating Cash Flow
40.69BKRWFY2025 · Dec 31, 2025Free Cash Flow
33.25BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
28.85BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
40.29BKRWFY2025 · Dec 31, 2025Stock-based Compensation
850.58MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-539.88MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-4.32BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
4.42BKRWFY2025 · Dec 31, 2025Capital Expenditures
-7.44BKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-37.96MKRWFY2025 · Dec 31, 2025Purchase of Investments
-34.90BKRWFY2025 · Dec 31, 2025Sale of Investments
10.08BKRWFY2025 · Dec 31, 2025Other Investing Activity
-23.46MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-32.29BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
14.00BKRWFY2025 · Dec 31, 2025Common Dividends Paid
-1.20BKRWFY2025 · Dec 31, 2025Other Financing Charges
-10.00KRWFY2025 · Dec 31, 2025Net Financing Cash Flow
12.80BKRWFY2025 · Dec 31, 2025Shares Outstanding
60.00MSharesUpdated Aug 20, 2026Float Shares
39.84MSharesUpdated Aug 20, 2026% Held by Insiders
9.56%vs all stocks
% Held by Institutions
5.90%vs all stocks
Total Cash (MRQ)
9.44BKRW6.80M · vs all stocks (USD)
Total Cash per Share (MRQ)
209.31KRWUpdated Aug 20, 2026Total Debt (MRQ)
11.74BKRW8.46M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1394xvs Biotechnology peers
Current Ratio (MRQ)
1.34xvs Biotechnology peers
Book Value per Share (MRQ)
2.21KKRWUpdated Aug 20, 2026Total Assets
157.17BKRW113.25M · vs all stocks (USD)
Total Current Assets
95.13BKRWFY2025 · Dec 31, 2025Total Liabilities
33.30BKRWFY2025 · Dec 31, 2025Total Non-current Assets
62.04BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
13.67BKRWFY2025 · Dec 31, 2025Total Current Liabilities
19.62BKRWFY2025 · Dec 31, 2025Cash Equivalents
28.85BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
28.85BKRWFY2025 · Dec 31, 2025Other Short-term Investments
27.99BKRWFY2025 · Dec 31, 2025Accounts Receivable
20.75BKRWFY2025 · Dec 31, 2025Inventory
15.97BKRWFY2025 · Dec 31, 2025Accounts Payable
2.95BKRWFY2025 · Dec 31, 2025Short-term Debt
6.21BKRWFY2025 · Dec 31, 2025Other Current Liabilities
470.00KRWFY2025 · Dec 31, 2025Long-term Debt
8.37BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
1.35MKRWFY2025 · Dec 31, 2025Common Stock (Book)
30.01BKRWFY2025 · Dec 31, 2025Retained Earnings
43.72BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
123.88BKRW89.26M · vs all stocks (USD)
Treasury Stock
114.83MKRWFY2025 · Dec 31, 202552-Week Low
8.14KKRWUpdated Aug 20, 202652-Week High
21.15KKRWUpdated Aug 20, 202652-Week Change
10.02%vs all stocks
Beta
0.6210xvs all stocks
50-Day MA
11.95KKRWUpdated Aug 20, 2026200-Day MA
15.05KKRWUpdated Aug 20, 2026Avg 10-Day Volume
1.41MSharesUpdated Aug 20, 2026Avg 30-Day Volume
848.49KSharesUpdated Aug 20, 2026Diluted EPS (TTM)
671.00KRWUpdated Aug 20, 20268 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Cash-Flow Ratios Elevated
More of its sales turn into cash than in its industry, and less of that cash is consumed by reinvestment than at most of its peers.
Reads
FCF Ratios Elevated
Its free cash flow is large next to assets and equity, and more of its operating cash reaches it than in its industry.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
ROE, ROA, And Operating ROA Elevated
It earns more on its equity than its industry does, and on its assets too — not on borrowing alone.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
Is this company growing?
Growth With Volume Backing
Revenue and net income have compounded over six years, and volume has leaned up with it.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 29.72Revenue Growth YoY: -0.58
High gross margins eroded by operating costsNotable
Gross Margin: 0.47Profit Margin: -1.12
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $17.25M, lower than 95% of all stocks globallySignificant
Revenue (USD): 17,253,663.797Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Regenxbio Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Tibet Aim Pharm Inc.
Tier 1ProductionApproval-Gated PipelineRule
Eiken Chemical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Arvinas Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lifecome Biochemistry Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zura Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Valneva SE
Tier 1ProductionApproval-Gated PipelineRuleRisk
Aim Vaccine Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Pku Healthcare Corporation Limited
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Cheryong Electric Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedGrowth With Volume BackingIndustry-Benchmarked Return on Capital Elevated
Shenzhen Bingchuan Network Co., Ltd.
7 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedIndustry-Benchmarked Return on Capital Elevated
Shenzhen Coship Electronics Co., Ltd.
6 interpretationsMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total LiabilitiesMinimal Tax and Interest DragFCF Ratios ElevatedROE, ROA, And Operating ROA ElevatedCash-Flow Ratios ElevatedIndustry-Benchmarked Return on Capital Elevated